Eli Lilly Sees Financial Results For Q3 To Include Acquired IPR&D Representing Charge Of About $3.08 To Both GAAP & Non-GAAP EPS
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's Q3 financial results will include an acquired in-process research and development (IPR&D) charge of approximately $3.08, affecting both GAAP and non-GAAP EPS.
October 08, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's Q3 financial results will be impacted by a $3.08 charge related to acquired in-process research and development, affecting both GAAP and non-GAAP EPS.
The $3.08 charge for acquired IPR&D will directly reduce Eli Lilly's earnings per share for Q3, which is likely to have a negative short-term impact on the stock price as it affects both GAAP and non-GAAP EPS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100